Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

543
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
543
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.1K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.1K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.4K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.4K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

968
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
968

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of pharmacy education and pharmacy practice in developing pharmacists as researchers in Austria.

The International journal of pharmacy practice·2026
Same author

Patient and Physician Perspectives on Pharmacotherapy in Parkinson's Disease Psychosis: A Mixed-Methods Exploratory Study.

Pharmacy (Basel, Switzerland)·2026
Same author

Final destination - pharmacists' perspectives on assisted suicide (the PAS-study): a cross-sectional convergent parallel mixed-methods study.

Journal of pharmaceutical policy and practice·2026
Same author

Community Pharmacist Prescribing: Roles and Competencies-A Systematic Review and Implications.

Pharmacy (Basel, Switzerland)·2025
Same author

Drug shortages: clinical implications and burdens - a trinational multiple-methods study including key stakeholders.

Journal of pharmaceutical policy and practice·2025
Same author

Pharmacist-Led Prescribing in Austria: A Mixed-Methods Study on Clinical Readiness and Legal Frameworks.

Pharmacy (Basel, Switzerland)·2025

Related Experiment Video

Updated: Feb 8, 2026

Intracranial Pharmacotherapy and Pain Assays in Rodents
02:26

Intracranial Pharmacotherapy and Pain Assays in Rodents

Published on: April 9, 2019

5.9K

Pharmacotherapy in Parkinson’s disease.

Olaf Rose

    Medizinische Monatsschrift Fur Pharmazeuten
    |June 29, 2018
    PubMed
    Summary

    Parkinson's disease pharmacotherapy relies on dopaminergic stimulation. Recent clinical experience highlights improved efficacy and duration with MAO-B inhibitors, though advanced stages remain challenging.

    Area of Science:

    • Neurology
    • Pharmacology
    • Clinical Medicine

    Background:

    • Parkinson's disease pharmacotherapy is complex, centering on dopaminergic stimulation.
    • Limited new drug development in the past decade necessitates optimizing existing treatments.
    • Clinical experience is advancing, offering new insights into treatment efficacy.

    Purpose of the Study:

    • To review the current landscape of Parkinson's disease pharmacotherapy.
    • To highlight recent advancements and clinical experiences with existing drug classes.
    • To discuss the challenges in managing advanced Parkinson's disease.

    Main Methods:

    • Review of recent clinical studies and experience.
    • Analysis of the efficacy and duration of MAO-B inhibitors.

    More Related Videos

    Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
    06:07

    Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

    Published on: June 23, 2023

    2.3K
    Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
    07:31

    Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

    Published on: January 7, 2019

    8.6K

    Related Experiment Videos

    Last Updated: Feb 8, 2026

    Intracranial Pharmacotherapy and Pain Assays in Rodents
    02:26

    Intracranial Pharmacotherapy and Pain Assays in Rodents

    Published on: April 9, 2019

    5.9K
    Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
    06:07

    Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

    Published on: June 23, 2023

    2.3K
    Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
    07:31

    Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

    Published on: January 7, 2019

    8.6K
  • Assessment of therapeutic challenges in advanced Parkinson's disease.

    • Main Results:

    • MAO-B inhibitors show promising results for better and longer efficacy.
    • Clinical experience has progressed significantly despite limited new drug registrations.
    • Advanced Parkinson's disease presents challenges due to a narrowing therapeutic window and prevalent motor complications.

    Conclusions:

    • Optimizing existing therapies, like MAO-B inhibitors, is crucial for Parkinson's disease management.
    • Continued clinical experience is vital for refining treatment strategies.
    • Addressing motor complications in advanced stages remains a key therapeutic challenge.